Phathom Pharmaceuticals annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Stock-Based Compensation Growth & History (PHAT)
Phathom Pharmaceuticals's stock-based compensation was $28.7M for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $28.7M | $4.7M | +19.43% |
| 2024 | 2024-12-31 | $24.0M | −$21.0M | −46.59% |
| 2023 | 2023-12-31 | $45.0M | $20.9M | +86.57% |
| 2022 | 2022-12-31 | $24.1M | $7.3M | +43.55% |
| 2021 | 2021-12-31 | $16.8M | $11.0M | +187.88% |
| 2020 | 2020-12-31 | $5.8M | $5.4M | +1338.42% |
| 2019 | 2019-12-31 | $406,000 | — | — |
Phathom Pharmaceuticals quarterly stock-based compensation
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.7M | −$1.6M | −18.86% |
| Q1 2026 | 2026-03-31 | $5.5M | −$6,000 | −0.11% |
| Q4 2025 | 2025-12-31 | $5.6M | −$1.1M | −16.11% |
| Q3 2025 | 2025-09-30 | $9.3M | $3.7M | +64.99% |
| Q2 2025 | 2025-06-30 | $8.3M | $2.2M | +35.63% |
| Q1 2025 | 2025-03-31 | $5.5M | −$86,000 | −1.53% |
| Q4 2024 | 2024-12-31 | $6.7M | −$17.9M | −72.80% |
| Q3 2024 | 2024-09-30 | $5.6M | −$505,000 | −8.22% |
| Q2 2024 | 2024-06-30 | $6.1M | −$1.2M | −15.91% |
| Q1 2024 | 2024-03-31 | $5.6M | −$1.4M | −20.18% |
| Q4 2023 | 2023-12-31 | $24.6M | $17.9M | +269.30% |
| Q3 2023 | 2023-09-30 | $6.1M | $324,000 | +5.57% |
| Q2 2023 | 2023-06-30 | $7.3M | $1.4M | +23.25% |
| Q1 2023 | 2023-03-31 | $7.0M | $1.3M | +22.04% |
| Q4 2022 | 2022-12-31 | $6.7M | $2.3M | +53.46% |
| Q3 2022 | 2022-09-30 | $5.8M | $1.4M | +31.61% |
| Q2 2022 | 2022-06-30 | $5.9M | $1.6M | +38.90% |
| Q1 2022 | 2022-03-31 | $5.8M | $2.0M | +51.26% |
| Q4 2021 | 2021-12-31 | $4.3M | $2.0M | +82.35% |
| Q3 2021 | 2021-09-30 | $4.4M | $2.3M | +113.48% |
| Q2 2021 | 2021-06-30 | $4.2M | $3.4M | +411.71% |
| Q1 2021 | 2021-03-31 | $3.8M | $3.3M | +578.15% |
| Q4 2020 | 2020-12-31 | $2.4M | — | — |
| Q3 2020 | 2020-09-30 | $2.1M | $2.0M | +5494.59% |
| Q2 2020 | 2020-06-30 | $828,000 | $799,000 | +2755.17% |
| Q1 2020 | 2020-03-31 | $563,000 | — | — |
| Q3 2019 | 2019-09-30 | $37,000 | — | — |
| Q2 2019 | 2019-06-30 | $29,000 | — | — |
Phathom Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Phathom Pharmaceuticals's stock-based compensation increased from $5.8M to $28.7M, a change of $22.9M. The latest reported quarter, Q2 2026, shows $6.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗